Novartis Leads Way in Big Pharma Growth

Novartis Leads Way in Big Pharma Growth
 
New York, NY June 30, 2010 - Novartis is forecast to deliver the strongest prescription pharmaceutical sales growth of any Big Pharma company over the period 2009-15, based on organic performance, finds independent market analyst Datamonitor.
 
The organisation is expected to deliver a compound annual growth rate (CAGR) of over 4% which would add more than $10 billion to sales.
 
Over the same period Datamonitor is forecasting an average of just 1.4% CAGR for Big Pharma generally.
 
Simon King, PharmaVitae* analyst at Datamonitor said: "Integral to Novartis delivering a sales growth performance well above average is the company's heavily diversified prescription pharmaceutical offering. "
 
Structurally the company's prescription pharmaceuticals business comprises the second largest global generics player Sandoz; whilst its vaccine business, which it inherited via the acquisition of Chiron, is the industry's fifth largest vaccine business.
 
Simon concludes: "Whilst exposure of blockbuster brands to generic competition from 2011 onwards will decelerate sales growth from the branded pharmaceuticals portfolio, neither the vaccine or Sandoz businesses will be exposed to a directly comparable competitive threat. This is an inherent factor that has both driven Novartis's investment in these market segments and which will dictate stronger sales growth performances for these units over 2009-15."
 
 
Ends
 
 
Notes for editors
 
* Datamonitor's PharmaVitae team covers the top 50 companies operating in the prescription pharmaceutical market, which account for an estimated 70% of annual industry sales. The team consists of a number of dedicated company analysts, who work closely with Datamonitor's disease team analysts to offer in depth analysis of the prescription pharmaceutical industry from a corporate perspective.
Simon King is available for comment.
To arrange an interview or for further details regarding this release please contact Alicia Barrios in the Datamonitor press office on +1 570 687 9319, or email [email protected]
 
For UK, please contact Joe Dixon on + 44 (0)161 238 4083. For Asia-Pacific, please contact Tanisha Kaul on +61 (0) 9601 6723. For India/Middle-East, please contact Aartee Sundheep on + 91 (40) 6672 9586
 
 
ABOUT DATAMONITOR
The Datamonitor Group (www.datamonitor.com) is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. Combining our industry knowledge and experience, we assist more than 6,000 of the world's leading companies in making better strategic and operational decisions.  
 
 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.